Donor cells, when used to treat a patient, have the capacity to be rejected by the recipient as they can be recognised as ‘non-self’. TCB is currently developing a new universal stem cell treatment, OmniCytex®, which will overcome this limitation. OmniCytex® can be used to generate multiple cell types with differing properties with numerous clinical applications.

OmniCytex® is characterised by;

  • Minimal risk of rejection

  • An ethical and abundant cellular source

  • Pluripotent characteristics but no tumorigenicity

Clinical Trials
In Market